ECSP099593A - Derivados de indol - Google Patents
Derivados de indolInfo
- Publication number
- ECSP099593A ECSP099593A EC2009009593A ECSP099593A ECSP099593A EC SP099593 A ECSP099593 A EC SP099593A EC 2009009593 A EC2009009593 A EC 2009009593A EC SP099593 A ECSP099593 A EC SP099593A EC SP099593 A ECSP099593 A EC SP099593A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- pain
- alkyloxy
- hydrogen
- optionally substituted
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 208000002193 Pain Diseases 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 abstract 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 206010058019 Cancer Pain Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 239000005977 Ethylene Chemical group 0.000 abstract 1
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 229940121376 cannabinoid receptor agonist Drugs 0.000 abstract 1
- 239000003537 cannabinoid receptor agonist Substances 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000018198 spasticity Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se relaciona a derivados de indol que tienen la Fórmula genera (I) en donde A representa un anillo heterocíclico aromático de 5 miembros, en donde X1, X2 y X3 son independientemente seleccionados entre N, O, S y CH; Y representa CH2, O, S o SO2; R1 es H, (C1-4)alquilo, (C1-4)alquiloxi, CN o halógeno; R2, R2', R3, R3', R4, R4', R5 y R5' son independientemente hidrógeno,(C1-4)alquilo (opcionalmente sustituido con OH) o CO-OR8; o un par de sustituyentes geminales R3 y R3' o R5 y R5' en conjunto representan un grupo ceto, y los otros todos son hidrógeno o (C1-4)alquilo; o R2 y R5 en conjunto representan un puente metileno o uno etileno, y R2', R3, R3', R4, R4' y R5' son hidrógeno; n es 1 ó 2; R6 es H, (C1-4)alquilo (opcionalmente sustituido con OH, (C1-4)alquiloxi, CO-NR9R10, CO-OR11 o 1,2,4-oxadiazol-3-il), SO2NR12R13 o COOR14; R7 es H o halógeno; R8 es (C1-4)alquilo; R9 y R10 son independientemente hidrógeno, (C1-4)alquilo o (C3-7)cicloalquilo, los grupos alquilo siendo opcionalmente sustituidos con OH o (C1-4)alquiloxi; R11 es H o (C1-4)alquilo; R12 y R13 son independientemente H o (C1-4)alquilo; R14 es (C1-6)alquilo; o una sal farmacéuticamente aceptable del mismo, como agonistas del receptor canabinoide CB1, el cual puede ser usado en el tratamiento de dolor tal como por ejemplo dolor peri operativo, dolor crónico, dolor neuropático, dolor de cáncer y dolor y espasticidad asociada a esclerosis múltiple.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07102870 | 2007-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP099593A true ECSP099593A (es) | 2009-09-29 |
Family
ID=38283196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2009009593A ECSP099593A (es) | 2007-02-22 | 2009-08-21 | Derivados de indol |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7655645B2 (es) |
| EP (1) | EP2125795B1 (es) |
| JP (1) | JP5324476B2 (es) |
| KR (1) | KR20090113383A (es) |
| CN (1) | CN101616914B (es) |
| AR (1) | AR065393A1 (es) |
| AU (1) | AU2008219226B2 (es) |
| BR (1) | BRPI0807867A2 (es) |
| CA (1) | CA2678147A1 (es) |
| CL (1) | CL2008000514A1 (es) |
| EC (1) | ECSP099593A (es) |
| IL (1) | IL199848A0 (es) |
| MX (1) | MX2009008316A (es) |
| PE (1) | PE20090112A1 (es) |
| RU (1) | RU2009135255A (es) |
| TW (1) | TW200848417A (es) |
| WO (1) | WO2008101995A1 (es) |
| ZA (1) | ZA200905265B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI330635B (en) | 2004-03-05 | 2010-09-21 | Organon Nv | (indol-3-yl)-heterocycle derivatives |
| US7763732B2 (en) * | 2005-08-24 | 2010-07-27 | N.V. Organon | Indole derivatives |
| TW200848417A (en) | 2007-02-22 | 2008-12-16 | Organon Nv | Indole derivatives |
| WO2010036998A2 (en) * | 2008-09-29 | 2010-04-01 | Abbott Laboratories | Indole and indoline derivatives and methods of use thereof |
| US9332757B2 (en) | 2010-10-25 | 2016-05-10 | Vanderbilt University | Composition for inhibition of insect host sensing |
| AU2012254032B2 (en) | 2011-05-06 | 2017-02-23 | Vanderbilt University | Compositions for inhibition of insect sensing |
| CN102757427A (zh) * | 2012-07-09 | 2012-10-31 | 陕西科技大学 | 2-氨基-5-异二氢吲哚-1,3-二酮甲基1,3,4-噻二唑及其制备方法 |
| US10791739B2 (en) | 2015-03-25 | 2020-10-06 | Vanderbilt University | Binary compositions as disruptors of orco-mediated odorant sensing |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4939138A (en) * | 1988-12-29 | 1990-07-03 | Sterling Drug Inc. | 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo(1,2,3-DE)-1,4-benzoxazines |
| TWI292316B (en) * | 1999-10-11 | 2008-01-11 | Sod Conseils Rech Applic | Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof |
| US6653304B2 (en) | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| AUPR118000A0 (en) | 2000-11-02 | 2000-11-23 | Amrad Operations Pty. Limited | Therapeutic molecules and methods |
| JP2005503998A (ja) | 2001-01-29 | 2005-02-10 | ユニバーシティ オブ コネチカット | 受容体選択性のカンナビミメティックアミノアルキルインドール |
| TWI248438B (en) * | 2001-04-10 | 2006-02-01 | Sod Conseils Rech Applic | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
| TW200402417A (en) | 2002-06-21 | 2004-02-16 | Akzo Nobel Nv | 1-[(Indol-3-yl)carbonyl]piperazine derivatives |
| BRPI0417626A (pt) | 2003-12-17 | 2007-03-27 | Akzo Nobel Nv | derivado de 1-[(indol-3-il) carbonil] piperazina tricìclica, composição farmacêutica, uso de um derivado de 1-[(indol-3-il) carbonil] piperazina tricìclica |
| TWI330635B (en) | 2004-03-05 | 2010-09-21 | Organon Nv | (indol-3-yl)-heterocycle derivatives |
| AU2006268680B2 (en) * | 2005-07-11 | 2012-11-22 | Msd Oss B.V. | Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist) |
| TW200745096A (en) | 2005-08-23 | 2007-12-16 | Organon Nv | Indole derivatives |
| US7763732B2 (en) * | 2005-08-24 | 2010-07-27 | N.V. Organon | Indole derivatives |
| TW200848417A (en) | 2007-02-22 | 2008-12-16 | Organon Nv | Indole derivatives |
-
2008
- 2008-01-29 TW TW097103332A patent/TW200848417A/zh unknown
- 2008-02-15 US US12/031,851 patent/US7655645B2/en not_active Expired - Fee Related
- 2008-02-20 PE PE2008000362A patent/PE20090112A1/es not_active Application Discontinuation
- 2008-02-20 AR ARP080100681A patent/AR065393A1/es unknown
- 2008-02-20 CL CL200800514A patent/CL2008000514A1/es unknown
- 2008-02-21 CA CA002678147A patent/CA2678147A1/en not_active Abandoned
- 2008-02-21 AU AU2008219226A patent/AU2008219226B2/en not_active Ceased
- 2008-02-21 WO PCT/EP2008/052141 patent/WO2008101995A1/en not_active Ceased
- 2008-02-21 MX MX2009008316A patent/MX2009008316A/es active IP Right Grant
- 2008-02-21 BR BRPI0807867-0A2A patent/BRPI0807867A2/pt not_active IP Right Cessation
- 2008-02-21 EP EP08709170A patent/EP2125795B1/en active Active
- 2008-02-21 CN CN2008800057712A patent/CN101616914B/zh not_active Expired - Fee Related
- 2008-02-21 KR KR1020097019668A patent/KR20090113383A/ko not_active Withdrawn
- 2008-02-21 RU RU2009135255/04A patent/RU2009135255A/ru not_active Application Discontinuation
- 2008-02-21 JP JP2009550715A patent/JP5324476B2/ja not_active Expired - Fee Related
-
2009
- 2009-07-14 IL IL199848A patent/IL199848A0/en unknown
- 2009-07-28 ZA ZA200905265A patent/ZA200905265B/xx unknown
- 2009-08-21 EC EC2009009593A patent/ECSP099593A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200848417A (en) | 2008-12-16 |
| EP2125795A1 (en) | 2009-12-02 |
| RU2009135255A (ru) | 2011-03-27 |
| PE20090112A1 (es) | 2009-02-26 |
| CL2008000514A1 (es) | 2008-06-20 |
| KR20090113383A (ko) | 2009-10-30 |
| ZA200905265B (en) | 2010-04-28 |
| US20080207598A1 (en) | 2008-08-28 |
| CN101616914A (zh) | 2009-12-30 |
| AU2008219226A1 (en) | 2008-08-28 |
| BRPI0807867A2 (pt) | 2014-06-03 |
| US7655645B2 (en) | 2010-02-02 |
| JP2010519278A (ja) | 2010-06-03 |
| IL199848A0 (en) | 2010-04-15 |
| AR065393A1 (es) | 2009-06-03 |
| JP5324476B2 (ja) | 2013-10-23 |
| AU2008219226B2 (en) | 2013-02-07 |
| EP2125795B1 (en) | 2013-03-20 |
| CN101616914B (zh) | 2012-10-10 |
| WO2008101995A1 (en) | 2008-08-28 |
| MX2009008316A (es) | 2009-08-12 |
| CA2678147A1 (en) | 2008-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP099593A (es) | Derivados de indol | |
| AR099023A1 (es) | Pirazolil-heteroarilamidas como agentes plaguicidas | |
| CY1110651T1 (el) | Παραγωγα της ν-'(1,5-διφαινυλ-1η- πυραζολ-3-υλ)μεθυλ σουλφοναμιδης με μια συγγενεια για τους υποδοχεις cb1 | |
| AR076753A1 (es) | Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides. | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR106945A2 (es) | Compuestos de isoindolina y composiciones farmacéuticas de los mismos | |
| AR078311A1 (es) | Derivados de tiadiazol como agonistas de los receptores de esfingosina-1-fosfato (s1p1) | |
| PE20081838A1 (es) | Derivados de ester o amida de imidazolilo como moduladores del receptor glucocorticoide | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR064874A1 (es) | Derivados de hexahidro y tetrahidropterinas,composiciones farmaceuticas que los contienen y usos de las mismas en trastornos cardiovasculares y psiquiatricos entre otros | |
| ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| AR083003A1 (es) | Lactamas sustituidas por piperidinilo como moduladores de gpr119 | |
| HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
| PE20140934A1 (es) | Derivados de pirazol | |
| MX2010006202A (es) | Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
| AR079077A1 (es) | Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica de enfermedades mediadas por la tirosina quinasa | |
| AR058010A1 (es) | Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto | |
| AR065587A1 (es) | Aminoamidas como antagonistas de orexina | |
| EA200970705A1 (ru) | Новые фармацевтические композиции | |
| CO6160310A2 (es) | Nuevos derivados imidazolonas su preparacion como medicamentos composiciones farmaceuticas utilizacion como inhibidores de proteinas quinasas principalmente cdc7 | |
| AR086024A1 (es) | Derivados de 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina carboxamidas | |
| AR054790A1 (es) | Metodos para el tratamiento de disfuncion sexual | |
| ES2479718T3 (es) | Nuevos derivados de tetrahidroquinolina |